International Agency for Research on Cancer (IARC) - Summaries & Evaluations
VOL.: 31 (1983) (p. 141)
CAS No.: 67-45-8
Chem. Abstr. Name: 2-Oxazolidinone, 3-([(5-nitro-2-furanyl)methylene]amino)-
5. Summary of Data Reported and Evaluation
5.1 Experimental data
Data on the carcinogenicity of furazolidone were reported only in
secondary sources and therefore could not be evaluated. (See 'General Remarks
on the Substances Considered', in this volume.)
Furazolidone has been shown to induce DNA damage and mutations in
bacteria and mutations in fungi and insects. It caused unscheduled
DNA synthesis in mammalian cells in vitro and yielded conflicting
results when tested for chromosomal anomalies in human cells in vitro.
There is sufficient evidence that furazolidone is active in short-term
Furazolidone induced abortion in mice. The data were inadequate
to evaluate other prenatal effects.
5.2 Human data
Furazolidone has been produced commercially since 1955. It is
used in human and veterinary medicine as an antibacterial and
No data were available to assess the teratogenicity or
chromosomal effects of this compound in humans.
No case report or epidemiological study of the carcinogenicity of
furazolidone was available to the Working Group.
No evaluation of the carcinogenicity of furazolidone to
experimental animals could be made. In the absence of epidemiological
data, no evaluation of the carcinogenicity of furazolidone to humans
could be made.
Subsequent evaluation: Suppl. 7 (1987) (p. 63: Group 3)
- Furoxone Swine Mix
- NF 180
- NF 180 Custom Mix Ten
Last updated: 16 April 1998